{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:57:22Z","timestamp":1791341842572,"version":"4.3.1"},"reference-count":159,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Sino-nasal disease is appropriately treated with topical treatment, where the nasal mucosa acts as a barrier to systemic absorption. Non-invasive nasal delivery of drugs has produced some small molecule products with good bioavailability. With the recent COVID pandemic and the need for nasal mucosal immunity becoming more appreciated, more interest has become focused on the nasal cavity for vaccine delivery. In parallel, it has been recognized that drug delivery to different parts of the nose can have different results and for \u201cnose-to-brain\u201d delivery, deposition on the olfactory epithelium of the upper nasal space is desirable. Here the non-motile cilia and reduced mucociliary clearance lead to longer residence time that permits enhanced absorption, either into the systemic circulation or directly into the CNS. Many of the developments in nasal delivery have been to add bioadhesives and absorption\/permeation enhancers, creating more complicated formulations and development pathways, but other projects have shown that the delivery device itself may allow more differential targeting of the upper nasal space without these additions and that could allow faster and more efficient programs to bring a wider range of drugs\u2014and vaccines\u2014to market.<\/jats:p>","DOI":"10.3390\/pharmaceutics15061720","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T01:32:15Z","timestamp":1686706335000},"page":"1720","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["The Upper Nasal Space: Option for Systemic Drug Delivery, Mucosal Vaccines and \u201cNose-to-Brain\u201d"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9892-3695","authenticated-orcid":false,"given":"Stephen B.","family":"Shrewsbury","sequence":"first","affiliation":[{"name":"Formerly of Impel Pharmaceuticals, 201 Elliott Ave West, Seattle, WA 98119, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113933","DOI":"10.1016\/j.biopha.2022.113933","article-title":"Applications and research progress of Traditional Chinese medicine delivered via nasal administration","volume":"157","author":"Hou","year":"2013","journal-title":"Biomed. Pharmacother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.17795\/jjnpp-9990","article-title":"Nasal Drug Delivery in Traditional Persian Medicine","volume":"8","author":"Zarshenas","year":"2013","journal-title":"Jundishapur. J. Nat. Pharm. Prod."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jconrel.2012.01.024","article-title":"Nasal Drug Delivery\u2014Recent developments and future prospects","volume":"161","author":"Ilum","year":"2012","journal-title":"J. Con. Rel."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"De la Torre, B.G., and Albericio, F. (2023). The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules, 28.","DOI":"10.3390\/molecules28031038"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11481-006-9039-x","article-title":"Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS","volume":"2","author":"Hanson","year":"2007","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1002\/jps.21604","article-title":"Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system","volume":"98","author":"Dhuria","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2741\/s252","article-title":"Intranasal treatment of neurodegenerative diseases and stroke","volume":"4","author":"Gomez","year":"2012","journal-title":"Front. Biosci. Schol. Ed."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/mp100029t","article-title":"Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures","volume":"7","author":"Johnson","year":"2010","journal-title":"Mol. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2200057120","DOI":"10.1073\/pnas.2200057120","article-title":"Intranasal delivery of full-length anti-Nogo-A antibody: A potential alternative route for therapeutic antibodies to central nervous system target","volume":"120","author":"Correa","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/17425247.2013.790887","article-title":"Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: An excellent platform for brain targeting","volume":"10","author":"Pardeshi","year":"2013","journal-title":"Expert. Opin. Drug Deliv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s11095-012-0915-1","article-title":"Intranasal Treatment of Central Nervous System Dysfunction in Humans","volume":"30","author":"Chapman","year":"2013","journal-title":"Pharm. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug Transport across the Blood-Brain Barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cerebr. Blood Flow Met."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2174\/1567201816666191029122740","article-title":"Drug Delivery and Targeting to the Brain Through the Nasal Route: Mechanisms, Applications and Challenges","volume":"16","author":"Kashyap","year":"2019","journal-title":"Curr. Drug Deliv."},{"key":"ref_14","first-page":"419","article-title":"Nasal Administration of Stem Cells: A Promising Novel Route to Treat Neonatal Ischemic Brain Damage","volume":"68","author":"Kavelaars","year":"2010","journal-title":"Pediatr. Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Crowe, T.P., and Hsu, W.H. (2022). Evaluation of Recent Intranasal Drug Delivery Systems to the Central Nervous System. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030629"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4155\/tde.14.41","article-title":"The Nasal Approach to Delivering Treatment for Brain Diseases: An Anatomic, Physiologic, and Delivery Technology Overview","volume":"5","author":"Djupesland","year":"2014","journal-title":"Ther. Deliv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal Delivery of Biologics to the Central Nervous System","volume":"64","author":"Lockhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/jcbfm.2014.215","article-title":"Rapid Transport within Perivascular Spaces Underlies Widespread Tracer Distribution in the Brain after Intranasal Administration","volume":"35","author":"Lockhead","year":"2015","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2017.11.041","article-title":"Nanoparticulate Peptide Delivery Exclusivity to the Brain Produces Tolerance Free Analgesia","volume":"270","author":"Godfrey","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ul Islam, S., Shehzad, A., Ahmed, M.B., and Lee, Y.S. (2020). Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders. Molecules, 25.","DOI":"10.3390\/molecules25081929"},{"key":"ref_21","first-page":"439","article-title":"Non-Invasive Stategies for Nose-to-Brain Drug Delivery","volume":"10","author":"Trevino","year":"2020","journal-title":"J. Clin. Trials"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev-cancerbio-030617-050558","article-title":"Prophylactic Vaccines for Nonviral Cancers","volume":"2","author":"Scott","year":"2018","journal-title":"Ann. Rev. Cancer Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"118813","DOI":"10.1016\/j.ijpharm.2019.118813","article-title":"Nasal Route for Vaccine and Drug Delivery: Features and Current Opportunities","volume":"572","author":"Mato","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","article-title":"Intranasal Drug Delivery: Opportunities and Toxicologic Challenges During Drug Development","volume":"12","author":"Keller","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40268-021-00360-5","article-title":"Improvement of Intranasal Delivery with Intravail\u00ae Alkylsaccharide Excipient as a Mucosal Absorption Enhancer Aiding in the Treatment of Conditions of the Central Nervous System","volume":"21","author":"Rabinowicz","year":"2021","journal-title":"Drug RD"},{"key":"ref_26","unstructured":"Suman, J. (ONdrugDelivery, 2021). How Evolving Patient Needs Have Fueled the Development of Nasal Drug Delivery, ONdrugDelivery."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.22159\/ajpcr.2019.v12i1.29443","article-title":"A Review on Nasal Drug Delivery System and its Contribution in Therapeutic Management","volume":"12","author":"Alnasser","year":"2019","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1124\/jpet.119.258152","article-title":"Nose-to-Brain Delivery","volume":"370","author":"Wang","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaci.2018.06.010","article-title":"NAVIGATE II: Randomized Double-blind Trial of the Exhalation Delivery System with Fluticasone for Nasal Polyposis","volume":"143","author":"Leopold","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/00005537-200404000-00022","article-title":"Origin of Nasal Polyps: An Endoscopic Autopsy Study","volume":"114","author":"Larsen","year":"2004","journal-title":"Laryngoscope"},{"key":"ref_31","unstructured":"(2023, June 09). Unidose (UDS) Liquid Nasal Spray System. Available online: https:\/\/aptar.com\/products\/pharmaceutical\/uds-unidose-liquid-nasal-spray-system\/."},{"key":"ref_32","unstructured":"(2023, June 09). Bidose (BDS) Liquid Nasal Spray System. Available online: https:\/\/aptar.com\/products\/pharmaceutical\/bds-bidose-nasal-spray-system-manufacturer\/."},{"key":"ref_33","unstructured":"(2023, June 09). Unidose (UDS) Powder Nasal Spray System. Available online: https:\/\/aptar.com\/products\/pharmaceutical\/unidose-nasal-powder-system-manufacturer\/#:~:text=Aptar%20Pharma%E2%80%99s%20Unidose%20(UDS)%20Nasal,precise%20dose%20quickly%20and%20easily."},{"key":"ref_34","unstructured":"(2023, June 09). VP3 Multi-Dose Spray Pump. Available online: https:\/\/aptar.com\/products\/pharmaceutical\/vp3-technology-platform\/."},{"key":"ref_35","unstructured":"(2023, June 09). Dihydroergotamine Mesylate. Available online: https:\/\/pi.bauschhealth.com\/globalassets\/BHC\/PI\/Migranal-PI.pdf."},{"key":"ref_36","unstructured":"(2023, June 09). Migranal. Available online: https:\/\/www.pdr.net\/drug-summary\/?drugLabelId=Migranal-dihydroergota-mine-mesylate-771."},{"key":"ref_37","unstructured":"(2023, June 09). Flonase Allergy Relief Nasal Spray. Available online: https:\/\/www.flonase.com\/products\/flonase-allergy-relief\/?gclid=CjwKCAi-Att2tBhBDEiwALZuhAEB-kI6eRoGWy2L-7zrmgp5zkSAX4ZcmpbvWvYIPwoRMvP0lijEufshoCvo8QAvD_BwE&gclsrc=aw.ds."},{"key":"ref_38","unstructured":"(2023, June 09). Trudhesa\u00ae. Available online: https:\/\/www.trudhesa.com\/."},{"key":"ref_39","unstructured":"(2023, June 09). Impel Pharmaceuticals. Available online: https:\/\/impelpharma.com\/our-science\/."},{"key":"ref_40","unstructured":"(2023, June 09). INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD (CALM 201), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05163717?cond=Autism&term=NCT05163717&rank=1."},{"key":"ref_41","unstructured":"(2023, June 09). The Future of Systemic and Central Nervous System (CNS) Therapies. Available online: https:\/\/kurvetx.com\/."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","article-title":"Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial","volume":"77","author":"Craft","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_43","unstructured":"(2023, June 09). XHANCE\u00ae (Fluticasone Propionate). Available online: https:\/\/www.optinose.com\/products\/xhance-fluticasone-propionate\/."},{"key":"ref_44","unstructured":"(2023, June 09). ONZETRA Xsail. Available online: https:\/\/www.onzetra.com\/."},{"key":"ref_45","unstructured":"(2023, June 09). STS101 (DHE Nasal Powder). Available online: https:\/\/www.satsumarx.com\/our-research\/sts101\/."},{"key":"ref_46","unstructured":"(2023, June 09). Aero Pump. Available online: https:\/\/www.aeropump.de\/en\/products\/nasal."},{"key":"ref_47","unstructured":"(2023, June 09). Metered Pump Nasal Spray Bottles, 1 oz. Available online: https:\/\/pharmasystems.com\/metered-pump-nasal-spray-bottles-1-oz-10271."},{"key":"ref_48","unstructured":"(2023, June 09). Healthcare Mark II\u2122. Available online: https:\/\/silgandispensing.com\/products\/mark-ii."},{"key":"ref_49","unstructured":"(2023, June 09). Nemera Ear, Nose, Throat. Available online: https:\/\/www.nemera.net\/wp-content\/uploads\/2021\/11\/Nemera-ENT-brochure-digital.pdf."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1080\/10717544.2022.2080889","article-title":"A Non-Invasive Direct Nose to Brain Drug Delivery Platform vs. Invasive Brain Delivery Approach: Patient-Centered Care Impact Analysis","volume":"29","author":"Frankenthal","year":"2022","journal-title":"Drug Deliv."},{"key":"ref_51","unstructured":"(2023, June 09). SipNose Nasal Delivery System. Available online: https:\/\/sipnose.com\/products\/."},{"key":"ref_52","unstructured":"(2023, June 09). MAD Nasal\u2122 Intranasal Mucosal Atomization Device. Available online: https:\/\/www.teleflex.com\/usa\/en\/product-areas\/anesthesia\/atomization\/mad-nasal-device\/."},{"key":"ref_53","unstructured":"(2023, March 24). Teleflex Intranasal Drug Delivery. Available online: https:\/\/teleflex.com\/usa\/en\/product-areas\/emergency-medicine\/intranasal-drug-delivery\/mad-nasal-intranasal-device\/index.html."},{"key":"ref_54","unstructured":"(2023, June 09). BD Accuspray\u2122 Nasal Spray System. Available online: https:\/\/www.bd.com\/en-us\/products-and-solutions\/products\/product-families\/accuspray-nasal-spray-system."},{"key":"ref_55","unstructured":"Becton Dickinson (2023, March 24). BD AccusprayTM Nasal Spray System. Available online: https:\/\/drugdeliverysystems.bd.com\/products\/prefillable-syringe-systems\/vaccine-syringes\/accuspray-nasal-spray-system."},{"key":"ref_56","unstructured":"(2023, June 09). The Potential and the Challenges of Nasal Vaccination. Available online: https:\/\/www.ondrugdelivery.com\/the-potential-and-the-challenges-of-nasal-vaccination\/."},{"key":"ref_57","unstructured":"Suman, J. (2023, January 2\u20135). Intranasal Vaccination: Rationale, Progress and Challenges. RDD Online 2023. Proceedings of the RDD 2023, Antibes (Nice), France."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/1073858420956905","article-title":"Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection","volume":"27","author":"Butowt","year":"2021","journal-title":"Neuroscientist"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41593-020-00758-5","article-title":"Olfactory Transmucosal SARS-CoV-2 Invasion as a Port of Central Nervous System Entry in Individuals with COVID-19","volume":"24","author":"Meinhardt","year":"2021","journal-title":"Nat. Neurosci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell\u2019s Palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"NEJM"},{"key":"ref_61","unstructured":"Scutti, S. (2016). CDC Panel Recommends against Using FluMist Vaccine, CNN Health."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"121180","DOI":"10.1016\/j.ijpharm.2021.121180","article-title":"Intranasal vaccine: Factors to consider in research and development","volume":"609","author":"Xu","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_63","unstructured":"Peace, R.M. (2015). Mucosal Immunization for Cancer: Opportunities and Challenges. [Master\u2019s Thesis, Dept of Pathology, Duke University]."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.4161\/hv.29269","article-title":"Novel Strategies and Applications for the Control of Pathogens and Tumors at Mucosal Sites","volume":"10","author":"Nizard","year":"2014","journal-title":"Hum. Vacc. Immunother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.3389\/fddev.2023.1164671","article-title":"On a Model-based Approach to Improve Intranasal Spray Targeting for Respiratory Viral Infections","volume":"3","author":"Akash","year":"2023","journal-title":"Front. Drug Deliv."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Soliman, H., Coffin, B., and Gourcerol, G. (2021). Gastroparesis in Parkinsons Disease: Pathophysiology and Clinical Management. Brain. Sci., 11.","DOI":"10.3390\/brainsci11070831"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/0333102412473371","article-title":"Gastric Stasis in Migraineurs: Etiology, Characteristics and Clinical and Therapeutic Implications","volume":"33","author":"Aurora","year":"2013","journal-title":"Cephalalgia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1007\/s11095-009-9871-9","article-title":"Clincial Study Shows Improved Absorption of Desmopressin with Novel Formulation","volume":"26","author":"Fransen","year":"2009","journal-title":"Pharm. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2018.06.011","article-title":"Chitosan-Coated Liposome Dry-Powder Formulations Loaded with Ghrelin for Nose-to-Brain Delivery","volume":"129","author":"Salade","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jconrel.2018.12.050","article-title":"Dispersable Hydrolytically Sensitive Nanoparticles for Nasal Delivery of Thyrotrophin Releasing Hormone (TRH)","volume":"295","author":"Zada","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/jphp.13317","article-title":"A CGRP Receptor Antagonist Peptide Formulated for Nasal Administration to Treat Migraine","volume":"72","author":"Russo","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Cloyd, J., Haut, S., Carrazana, E., and Rabinowicz, A.L. (2021). Overcoming the Challenges of Developing an Intranasal Diazepam Rescue Therapy for the Treatment of Seizure Clusters. Epilepsia, 62.","DOI":"10.1111\/epi.16847"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2125.2010.03611.x","article-title":"Pharmacokinetics and Pharmacodynamics of Nasally Delivered Midazolam","volume":"69","author":"Haschke","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_74","unstructured":"(2023, April 05). ZAVZPRETTM (zavegepant) Nasal Spray. Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216386s000lbl.pdf."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Martin, V., Hoekman, J., Aurora, S.K., and Shrewsbury, S.B. (2021). Nasal Delivery of Acute Medications for Migraine: The Upper Versus Lower Nasal Space. J. Clin. Med., 10.","DOI":"10.3390\/jcm10112468"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Moffa, A., Costantino, A., Rinaldi, V., Sabatino, L., Trecca, E.M.C., Baptista, P., Campisi, P., Cassano, M., and Casale, M. (2019). Nasal Delivery Devices: A comparative Study on Cadaver Model. BioMed. Res. Int., 2019.","DOI":"10.1155\/2019\/4602651"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1211\/jpp.58.10.0003","article-title":"Intranasal Midazolam: A Comparison of Two Delivery Devices in Human Volunteers","volume":"58","author":"Dale","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/01.MLG.0000199741.08517.99","article-title":"Breath Actuated Device Improves Delivery to Target Sites Beyond the Nasal Valve","volume":"116","author":"Djupesland","year":"2006","journal-title":"Laryngoscope"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1089\/jamp.2011.0924","article-title":"Nasal Deposition and Clearance in Man: Comparison of a Bidirectional Powder Device and a Traditional Liquid Nasal Spray","volume":"25","author":"Djupesland","year":"2012","journal-title":"J. Aerosol. Med. Pul. Drug Deliv."},{"key":"ref_80","unstructured":"Hoekman, J., Brunelle, A., Hite, M., Kim, P., and Fuller, C. (2013, January 10\u201314). SPECT Imaging of Direct Nose-to-Brain Transfer of MAG-3 in Man. Proceedings of the Am Assoc Pharm Scientist Annual Meeting, San Antonio, TX, USA."},{"key":"ref_81","unstructured":"Hoekman, J., Brunelle, A., Hite, M., Kim, P., and Fuller, C. (2013, January 10\u201314). Usability and Tolerability Study in Human Subjects with a Novel Precision Olfactory Delivery (POD) Device. Poster (M1050). Proceedings of the Am Assoc Pharm Scientist Annual Meeting, San Antonio, TX, USA."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2174\/156720112803529828","article-title":"Anatomical and Histological Factors Affecting Intranasal Drug and Vaccine Delivery","volume":"9","author":"Gizurarson","year":"2012","journal-title":"Curr. Drug Deliv."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/head.13476","article-title":"STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD\u00ae) Device, in Healthy Adult Subjects","volume":"59","author":"Shrewsbury","year":"2019","journal-title":"Headache"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/head.14184","article-title":"STOP 301: A Phase 3, Open-label Study of Safety, Tolerability and Exploratory Efficacy of INP104, Precision Olfactory Delivery (POD\u00ae) of Dihydroergotamine Mesylate over 24\/52 Weeks in Acute Treatment of Migraine Attacks in Adult patients","volume":"61","author":"Smith","year":"2021","journal-title":"Headache"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/head.13700","article-title":"Dihydroergotamine (DHE)\u2014Then and Now: A Narrative Review","volume":"60","author":"Silberstein","year":"2020","journal-title":"Headache"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1089\/jamp.2022.0005","article-title":"Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action","volume":"35","author":"Cooper","year":"2022","journal-title":"J. Aerosol. Med."},{"key":"ref_87","first-page":"1303","article-title":"The Upper Nasal Space as a Promising New Route for Drug Administration: Implications for Nasal Safety Assessments from the Pivotal STOP 301 Study of INP104","volume":"9","author":"Davis","year":"2022","journal-title":"Ann. Otolaryngol Rhinol."},{"key":"ref_88","first-page":"12","article-title":"SNAP 101: Double-Blind, Placebo\/Active-Controlled, Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of INP105 (nasal olanzapine) in Healthy Adults","volume":"81","author":"Shrewsbury","year":"2020","journal-title":"J. Clin. Psych."},{"key":"ref_89","first-page":"25","article-title":"The Upper Nasal Space\u2014A Novel Delivery Route Ideal for Central Nervous System Drugs","volume":"16","author":"Hoekman","year":"2020","journal-title":"US Neurol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"9","DOI":"10.18103\/mra.v10i9.2971","article-title":"The Pharmacokinetics of Drug Delivery to the Upper Nasal Space: A Review of INP105 Development","volume":"10","author":"Shrewsbury","year":"2022","journal-title":"Med. Res. Arch."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/ar.a.20122","article-title":"Distribution of Olfactory Epithelium in the Primate Nasal Cavity: Are Microsmia and Macrosmia Valid Morphological Concepts?","volume":"281A","author":"Smith","year":"2004","journal-title":"Anat. Rec."},{"key":"ref_92","first-page":"86","article-title":"Pfizer Exits Neuroscience","volume":"17","author":"Mullard","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_93","unstructured":"(2023, March 24). Special Report: 2022 Neurology Drug & Device Approvals. Pract. Neurol. 2023. Available online: https:\/\/practicalneurology.com\/articles\/2023-jan-feb\/special-report-2022-neurology-drug-device-approvals."},{"key":"ref_94","unstructured":"GBD 2016 neurology collaborators (2019). Global, regional, and national burden of neurological disorders, 1990\u20132016: A systematic analysis for the global burden of disease study 2016. Lancet Neurol., 18, 459\u2013480."},{"key":"ref_95","unstructured":"FDA Approves First Drug for Spinal Muscular Atrophy (2016). FDA News Release 23 December 2016, FDA."},{"key":"ref_96","unstructured":"(2023). FDA Approves Treatment of Amyotrophic Lateral Sclerosis Associated with a Mutation in the SOD1 Gene, FDA. FDA News Release 25 April 2023."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Alabsi, W., Eedara, B.B., Encinas-Basurto, D., Polt, R., and Mansour, H.M. (2022). Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14091870"},{"key":"ref_98","unstructured":"(2023, March 09). Peptide Therapeutics Market to Reach US$91.25bn by 2031. Available online: https:\/\/www.transparencymarketresearch.com\/peptide-therapeutics-market.html."},{"key":"ref_99","unstructured":"Nasal Drug Formulation: A Guide to Successful Drug Product Development (2023, March 09). LLS Health CDMO. 17 February 2021. Available online: https:\/\/lubrizolcdmo.com\/blog\/a-guide-to-the-successful-development-of-nasal-drug-formulations\/."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3233\/JAD-161256","article-title":"Effects of Regular and Long-acting Insulin on Cognition and Alzheimer\u2019s Disease Biomarkers: A Pilot Clinical Trial","volume":"57","author":"Craft","year":"2017","journal-title":"J. Alzheimers. Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/7854_2017_24","article-title":"Oxytocin and Autism Spectrum Disorders","volume":"35","author":"Yamasue","year":"2018","journal-title":"Curr. Top Behav. Neurosci."},{"key":"ref_102","first-page":"26","article-title":"Narcolepsy and Orexins: An Example of Progress in Sleep Research","volume":"2","year":"2011","journal-title":"Front. Neurol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"675725","DOI":"10.3389\/fphar.2021.675725","article-title":"FGF, Mechanism of Action, Role in Parkinson\u2019s Disease and Therapeutics","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_104","first-page":"6","article-title":"Intranasal Leptin Relieves Sleep-disordered Breathing in Mice with Diet-induced Obesity","volume":"199","author":"Berger","year":"2018","journal-title":"Am. J. Resp. Crit. Care Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2337\/db14-1000","article-title":"Intranasal Insulin Enhanced Resting-state Functional Connectivity of Hippocampal Regions in Type 2 Diabetes","volume":"64","author":"Zhang","year":"2015","journal-title":"Diabetes"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"790","DOI":"10.18632\/aging.101192","article-title":"Effect of Intranasally Administered Insulin on Cerebral Blood Flow and Perfusion: A Randomized Experiment in Young and Older Adults","volume":"9","author":"Akintola","year":"2017","journal-title":"Aging (Albany NY)"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2337\/dc13-1672","article-title":"Enhancement of Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes","volume":"37","author":"Novak","year":"2014","journal-title":"Diabetes Care."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2008-13309","article-title":"Intranasal Insulin Administration Dose-dependently Modulates Verbal Memory and Plasma Amyloid-\u00df in Memory-impaired Older Adults","volume":"13","author":"Reger","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/dom.13279","article-title":"Safety of intranasal human insulin: A review","volume":"20","author":"Schmid","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0031-9384(04)00348-8","article-title":"Insulin and the CNS: Effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans","volume":"83","author":"Stockhorst","year":"2004","journal-title":"Physiol. Behav."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Pandey, A., Nikam, A., Basavraj, S., Mutalik, S., Gopalan, D., Kulkarni, S., Padya, B., Fernandes, G., and Mutalik, S. (2021). Nose-To-Brain Drug Delivery: Regulatory Aspects, Clinical Trials, Patents, and Future Perspectives, Elsevier Inc.","DOI":"10.1016\/B978-0-12-822522-6.00023-0"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Rais, R., Wozniak, K., Wu, Y., Niwa, M., Stathis, M., Alt, J., Giroux, M., Sawa, A., Rojas, C., and Slusher, B.S. (2015). Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA Following Intranasal Administration. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0131861"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00213-008-1332-3","article-title":"Effect of Intranasally Administered Cholecystokinin on Encoding of Controlled and Automatic Memory Processes","volume":"202","author":"Schneider","year":"2009","journal-title":"Psychopharmacology."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Pedroso, I., Garcia, M., Casabona, E., Morales, L., Bringas, M.L., P\u00e9rez, L., Rodriguez, T., Sosa, I., Ricardo, Y., and Padron, A. (2018). Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson\u2019s Disease. Behav. Sci., 8.","DOI":"10.3390\/bs8050051"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/ijo.2011.105","article-title":"Intranasal Application of the Melanocortin 4 Receptor Agonist MSH\/ACTH(4\u201310) in Humans Causes Lipolysis in White Adipose Tissue","volume":"36","author":"Jacobs","year":"2012","journal-title":"Int. J. Obes."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3233\/JPD-161040","article-title":"Phase IIb Study of Intranasal Glutathione in Parkinson\u2019s Disease","volume":"7","author":"Mischley","year":"2017","journal-title":"J. Parkinsons. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Faria, G.M., Soares, I.D.P., D\u2019Alincourt Salazar, M., Amorim, M.R., Pessoa, B.L., Da Fonseca, C.O., and Quirico-Santos, T. (2020). Intranasal Perillyl Alcohol Therapy Improves Survival of Patients with Recurrent Glioblastoma Harboring Mutant Variant for MTHFR rs1801133 Polymorphism. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06802-8"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1161\/HYPERTENSIONAHA.113.02860","article-title":"Intranasal Angiotensin II in Humans Reduces Blood Pressure When Angiotensin II Type 1 Receptors are Blocked","volume":"63","author":"Derad","year":"2014","journal-title":"Hypertension"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3233\/ADR-180055","article-title":"Long-term Non-invasive Treatment via Intranasal Administration of Nerve Growth Factor Protects the Human Brain in Frontotemporal Dementia Associated with Corticobasal Syndrome: A Pilot Study","volume":"2","author":"Bellis","year":"2018","journal-title":"J. Alzheimers. Dis. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of Intranasal Drug Delivery Directly to the Brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/chemse\/bjaa070","article-title":"Maturation of the Olfactory Sensory Neuron and its Cilia","volume":"45","author":"McClintock","year":"2020","journal-title":"Chem. Senses"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/cne.902420410","article-title":"Endocytic and Exocytic Pathways of the Neuronal Secretory Process and Trans Synaptic Transfer of Wheat Germ Agglutinin-Horseradish Peroxidase in vivo","volume":"242","author":"Broadwell","year":"1985","journal-title":"J. Comp. Neuro"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/jpet.114.216705","article-title":"Intranasal Administration as a Route for Drug Delivery to the Brain: Evidence for a Unique Pathway for Albumin","volume":"351","author":"Falcone","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3233\/JAD-150307","article-title":"Central Nervous System Delivery on Intranasal Insulin: Mechanisms of Uptake and Effects on Cognition","volume":"47","author":"Salameh","year":"2015","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of Intranasal Delivery Route of Drug Administration for Brain Targeting","volume":"143","author":"Erdo","year":"2018","journal-title":"Brain Res. Bull."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1517\/17425247.5.10.1159","article-title":"From Nose to Brain: Understanding Transport Capacity and Transport Rate of Drugs","volume":"5","author":"Wu","year":"2008","journal-title":"Expert. Opin. Drug Deliv."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4155\/tde.11.149","article-title":"Nasal-to-CNS Drug Delivery: Where are we Now and Where are we Heading? An Industrial perspective","volume":"3","author":"Landis","year":"2012","journal-title":"Ther. Deliv."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/00003088-200241100-00001","article-title":"Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical Setting: Implications of the Barriers Between Blood and Brain","volume":"41","author":"Danhof","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"703944","DOI":"10.3389\/fncel.2021.703944","article-title":"Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease","volume":"15","author":"Derk","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ar.22415","article-title":"Histological and Ultrastructural Characteristics of the Primordial Vomeronasal Organ in Lungfish","volume":"295","author":"Nakamuta","year":"2012","journal-title":"Anat. Rec."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0896-6273(00)80946-0","article-title":"A New Multigene Family of Putative Pheromone Receptors","volume":"19","author":"Ryba","year":"1997","journal-title":"Neuron"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for Direct-to-Brain Delivery of Drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int. J. Pharm."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/17425247.3.4.529","article-title":"IntravailTM: Highly Effective intranasal Delivery of Peptide and Protein Drugs","volume":"3","author":"Maggio","year":"2006","journal-title":"Expert. Opin. Drug Deliv."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1517\/17425247.2014.931936","article-title":"Intranasal Formulations: Promising Strategy to Deliver Vaccines","volume":"11","author":"Riese","year":"2014","journal-title":"Expert. Opin. Drug Deliv."},{"key":"ref_135","first-page":"1","article-title":"Imaging of intranasal drug delivery to the brain","volume":"10","author":"Veronesi","year":"2020","journal-title":"Am. J. Nucl. Med. Mol. Imaging."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.2337\/dc14-2319","article-title":"Selective Insulin Resistance in Homeostatic and Cognitive Control Brain Areas in Overweight and Obese Adults","volume":"38","author":"Kullmann","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jconrel.2019.03.032","article-title":"Characterisation of Nasal Devices for Delivery of Insulin to the Brain and Evaluation in Humans Using Functional Magnetic Resonance Imaging","volume":"302","author":"Wingrove","year":"2019","journal-title":"JCR"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"8637","DOI":"10.1073\/pnas.1319810111","article-title":"Switching brain serotonin with oxytocin","volume":"111","author":"Mottolese","year":"2014","journal-title":"PNAS"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/mi.2010.55","article-title":"Topical Immunisation Strategies","volume":"3","author":"Czerkinsky","year":"2010","journal-title":"Mucosal Immunol"},{"key":"ref_140","first-page":"237","article-title":"The Waldeyer\u2019s Ring","volume":"54","author":"Hellings","year":"2000","journal-title":"Acta Otorhinolarngol. Belg."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1016\/j.vaccine.2015.07.022","article-title":"Mucosal Vaccination by the Intranasal Route. Nose-Associated Lymphoid Tissue (NALT)\u2014Structure, Function and Species Differences","volume":"26","author":"Pabst","year":"2015","journal-title":"Vaccine"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2249.2003.02311.x","article-title":"Nasal-associated lymphoid tissue (NALT): Frequency and localization in young children","volume":"134","author":"Debertin","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3389\/fimmu.2020.01383","article-title":"Norovirus Vaccine: Priorities for Future Research and Development","volume":"11","author":"Esposito","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_144","unstructured":"(2023, March 11). Moderna COVID-19 EUA Approval 2020. Available online: https:\/\/eua.modernatx.com\/covid19vaccine-eua\/fda-letter-eua.pdf."},{"key":"ref_145","unstructured":"(2023, March 11). Pfizer-BioNTech COVID-19 Vaccines 2021, Available online: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/pfizer-biontech-covid-19-vaccines."},{"key":"ref_146","unstructured":"Cohen, J. (2020). Chinese researchers reveal draft genome of virus implicated in Wuhan pneumonia outbreak. Science."},{"key":"ref_147","unstructured":"(2023, March 11). Janssen COVID-19 Vaccine 2021, Available online: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/janssen-covid-19-vaccine."},{"key":"ref_148","unstructured":"(2023, March 11). Novavax COVID-19 Vaccine, Adjuvenated 2022, Available online: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/novavax-covid-19-vaccine-adjuvanted."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/d41586-022-02851-0","article-title":"China and India approve nasal COVID vaccines\u2014Are they a game changer?","volume":"609","author":"Waltz","year":"2022","journal-title":"Nature"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"117607","DOI":"10.1016\/j.jns.2021.117607","article-title":"Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review","volume":"428","author":"Bahmanyar","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Li, Y.-D., Chi, W.-Y., Su, J.-H., Ferrall, L., Hung, C.-F., and Wu, T.-C. (2020). Coronavirus vaccine development: From SARS and MERS to COVID-19. J. Biomed. Sci., 27.","DOI":"10.1186\/s12929-020-00695-2"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"120994","DOI":"10.1016\/j.ijpharm.2021.120994","article-title":"Progress in nasal drug delivery systems","volume":"607","author":"Laffleur","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jconrel.2021.08.029","article-title":"Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines","volume":"338","author":"Blakney","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_154","first-page":"133","article-title":"Can Nasal Delivery Bypass the Blood-Brain Barrier?: Questionning the Direct Transport Theory","volume":"8","author":"Merkus","year":"2007","journal-title":"Drugs"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Jain, K.K. (2010). Vesicular Systems for Intranasal Drug Delivery. Drug Delivery to the Central Nervous System, Springer-Science.","DOI":"10.1007\/978-1-60761-529-3"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/aje\/kws011","article-title":"Immunization and Bell\u2019s Palsy in Children: A Case-centered Analysis","volume":"175","author":"Fireman","year":"2012","journal-title":"Am. J. Epidemiol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1021\/acs.molpharmaceut.0c00372","article-title":"Immunogenicity of Antigen Adjuvanted with AS04 and its Deposition in the Upper Respiratory Tract after Intranasal Administration","volume":"17","author":"Xu","year":"2020","journal-title":"Mol. Pharm."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/2231-4040.90876","article-title":"A review on mucoadhesive polymer used in nasal drug delivery system","volume":"2","author":"Chaturvedi","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Mendoca","year":"2021","journal-title":"npj Vaccines"}],"updated-by":[{"DOI":"10.3390\/pharmaceutics16060821","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000}}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/6\/1720\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T14:15:25Z","timestamp":1754230525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/6\/1720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":159,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["pharmaceutics15061720"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15061720","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]}}}